HomeCompareRUBY vs PM

RUBY vs PM: Dividend Comparison 2026

RUBY yields 3508.77% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RUBY wins by $2034141393542.03M in total portfolio value
10 years
RUBY
RUBY
● Live price
3508.77%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2034141393542.08M
Annual income
$1,926,153,862,282,748,700.00
Full RUBY calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — RUBY vs PM

📍 RUBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRUBYPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RUBY + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RUBY pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RUBY
Annual income on $10K today (after 15% tax)
$298,245.61/yr
After 10yr DRIP, annual income (after tax)
$1,637,230,782,940,336,400.00/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, RUBY beats the other by $1,637,230,782,940,334,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RUBY + PM for your $10,000?

RUBY: 50%PM: 50%
100% PM50/50100% RUBY
Portfolio after 10yr
$1017070696771.07M
Annual income
$963,076,931,141,375,600.00/yr
Blended yield
94.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

RUBY
Analyst Ratings
5
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
-81.9
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RUBY buys
0
PM buys
0
No recent congressional trades found for RUBY or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRUBYPM
Forward yield3508.77%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$2034141393542.08M$49.6K
Annual income after 10y$1,926,153,862,282,748,700.00$2,492.02
Total dividends collected$2026733119198.63M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: RUBY vs PM ($10,000, DRIP)

YearRUBY PortfolioRUBY Income/yrPM PortfolioPM Income/yrGap
1← crossover$361,577$350,877.19$11,648$408.29+$349.9KRUBY
2$12,243,821$11,856,933.69$13,589$495.90+$12.23MRUBY
3$388,336,948$375,236,059.53$15,877$603.21+$388.32MRUBY
4$11,538,279,357$11,122,758,822.00$18,580$734.88+$11538.26MRUBY
5$321,205,540,543$308,859,581,631.20$21,781$896.75+$321205.52MRUBY
6$8,379,307,864,544$8,035,617,936,162.96$25,578$1,096.12+$8379307.84MRUBY
7$204,877,671,222,196$195,911,811,807,134.25$30,092$1,342.17+$204877671.19MRUBY
8$4,695,974,086,156,479$4,476,754,977,948,728.50$35,470$1,646.46+$4695974086.12MRUBY
9$100,922,926,410,592,910$95,898,234,138,405,470.00$41,892$2,023.58+$100922926410.55MRUBY
10$2,034,141,393,542,082,800$1,926,153,862,282,748,700.00$49,578$2,492.02+$2034141393542.03MRUBY

RUBY vs PM: Complete Analysis 2026

RUBYStock

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Full RUBY Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this RUBY vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RUBY vs SCHDRUBY vs JEPIRUBY vs ORUBY vs KORUBY vs MAINRUBY vs MORUBY vs BTIRUBY vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.